The latest price target for Medpace Hldgs (NASDAQ:MEDP) was reported by Barclays on December 15, 2025. The analyst firm set a price target for $525.00 expecting MEDP to fall to within 12 months (a possible -7.71% downside). 25 analyst firms have reported ratings in the last year.

The latest analyst rating for Medpace Hldgs (NASDAQ:MEDP) was provided by Barclays, and Medpace Hldgs maintained their underweight rating.

The last upgrade for Medpace Holdings Inc happened on April 23, 2024 when Jefferies raised their price target to $450. Jefferies previously had a hold for Medpace Holdings Inc.

The last downgrade for Medpace Holdings Inc happened on October 2, 2025 when Barclays changed their price target from $450 to $425 for Medpace Holdings Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Medpace Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Medpace Hldgs was filed on December 15, 2025 so you should expect the next rating to be made available sometime around December 15, 2026.

While ratings are subjective and will change, the latest Medpace Hldgs (MEDP) rating was a maintained with a price target of $485.00 to $525.00. The current price Medpace Hldgs (MEDP) is trading at is $568.85, which is out of the analyst’s predicted range.